Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024)

Invivyd's (IVVD) quarterly Total Non-Current Liabilities came in at $62.0 million in Q4 2024, up 21.49% on a YoY basis from $51.0 million in Q1 2024, and down 21.31% quarter-over-quarter from $78.8 million in Q3 2024.

Analysis

Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends

Invivyd (IVVD) has reported Total Non-Current Liabilities for 5 consecutive years, with $62.0 million the latest figure, recorded in Q4 2024.

  • For the quarter ending Q4 2024, Total Non-Current Liabilities rose 21.49% year-over-year to $62.0 million; the trailing twelve-month figure through Dec 2024 stood at $62.0 million (up 21.49% YoY), and the FY2024 full-year result was $62.0 million, up 21.49% from the prior year.
  • Total Non-Current Liabilities fell to $62.0 million in Q4 2024 per IVVD's latest filing, from $78.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $96.9 million in Q1 2022 and bottomed at $13.1 million in Q4 2020.
  • Historically, Total Non-Current Liabilities has averaged $50.8 million across 5 years, with a median of $49.2 million in 2022.
  • The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities surged 374.4% in 2021, then slumped 56.18% in 2022.
  • Over 5 years, Total Non-Current Liabilities stood at $13.1 million in 2020, then soared by 374.4% to $62.1 million in 2021, then tumbled by 56.18% to $27.2 million in 2022, then jumped by 87.57% to $51.0 million in 2023, then rose by 21.49% to $62.0 million in 2024.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $62.0 million, $78.8 million, and $36.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 40.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 4.20 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 12.42 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 1.17 Bn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 61.98 Mn
Sep 30, 2024 78.76 Mn
Jun 30, 2024 36.70 Mn
Mar 31, 2024 36.97 Mn
Dec 31, 2023 51.01 Mn
Sep 30, 2023 27.72 Mn
Dec 31, 2022 27.20 Mn
Sep 30, 2022 47.30 Mn
Jun 30, 2022 69.77 Mn
Mar 31, 2022 96.88 Mn
Dec 31, 2021 62.07 Mn
Dec 31, 2020 13.08 Mn